Drugs / allogenic lyophilized growth factors
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04331327 Comparator | May 2017 → Apr 2018 | osteoarthritis, knee | Rasmia Elgohary | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogenic lyophilized growth factors | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04331327 ↗ |
| Known as | L-GFs | “Investigating the safety in addition to clinical and structural efficacy of allogenic lyophilized growth factors (L-GFs) in patients with symptomatic primary knee osteoarthritis.” PMID 33754800 ↗ Mar 2021 |
| Modality | Protein / enzyme biologic | “Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.” NCT04331327 ↗ |
| Route | Other | “Patients of the intervention group received two doses of intra-articular knee injections of allogenic lyophilized growth factors (L-GFs); one dose at the baseline and the other...” NCT04331327 ↗ |